Long-term safety and efficacy of pitavastatin in patients with acute myocardial infarction (from the Livalo acute myocardial infarction study [LAMIS])

Soon Yong Suh, Seung-Woon Rha, Tae Hoon Ahn, Eak Kyun Shin, Cheol Ung Choi, Dong Joo Oh, Jang Ho Bae, Seung Ho Hur, Kyung Ho Yoon, Seok Kyu Oh, Jong Hyun Kim, Sang Wook Kim, In Ho Chae, Kee Sik Kim, Young Joon Hong, Myung Ho Jeong

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Pitavastatin is a potent lipophilic statin and may play an important role in acute myocardial infarction (AMI) but there have been limited data on the safety and efficacy of pitavastatin in AMI. This study consisted of 1,039 consecutive patients with AMI (74.0% men, mean age 61.4 ± 12.6 years) who presented in 10 major percutaneous coronary intervention centers in Korea from February 2007 through September 2009. Pitavastatin 2 mg/day was routinely administered in patients with AMI from time of presentation. We investigated changes of lipid profiles, biochemical markers, adverse events, and clinical outcomes up to 12 months. During the study 318 events overall occurred in 220 patients (21.2%) who reported <1 treatment emergent adverse event, although 20 events in 14 patients (1.4%) were treatment-related adverse events. Low-density lipoprotein (LDL) cholesterol percent change was -25.6% and LDL cholesterol target attainment was 70.5% at 12-month follow-up. Levels of creatinine phosphokinase, serum glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, and high-sensitivity C-reactive protein decreased significantly during the first 1 month of pitavastatin treatment and were sustained to 12-month follow-up. Major adverse cardiac events occurred in 66 patients (7.3%). All-cause deaths occurred in 32 patients (3.5%) including 19 (2.1%) cardiac deaths and recurrent MIs occurred in 14 (1.6%) and target lesion revascularizations in 42 (4.7%). In conclusion, administration of pitavastatin 2 mg/day in patients with AMI showed 70.5% LDL cholesterol target attainment with good tolerance and was associated with favorable clinical outcomes up to 12 months.

Original languageEnglish
Pages (from-to)1530-1535
Number of pages6
JournalAmerican Journal of Cardiology
Volume108
Issue number11
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

Myocardial Infarction
Safety
LDL Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Percutaneous Coronary Intervention
Korea
Aspartate Aminotransferases
pitavastatin
Alanine Transaminase
C-Reactive Protein
Cause of Death
Creatinine
Phosphotransferases
Therapeutics
Biomarkers
Lipids

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Long-term safety and efficacy of pitavastatin in patients with acute myocardial infarction (from the Livalo acute myocardial infarction study [LAMIS]). / Suh, Soon Yong; Rha, Seung-Woon; Ahn, Tae Hoon; Shin, Eak Kyun; Choi, Cheol Ung; Oh, Dong Joo; Bae, Jang Ho; Hur, Seung Ho; Yoon, Kyung Ho; Oh, Seok Kyu; Kim, Jong Hyun; Kim, Sang Wook; Chae, In Ho; Kim, Kee Sik; Hong, Young Joon; Jeong, Myung Ho.

In: American Journal of Cardiology, Vol. 108, No. 11, 01.12.2011, p. 1530-1535.

Research output: Contribution to journalArticle

Suh, SY, Rha, S-W, Ahn, TH, Shin, EK, Choi, CU, Oh, DJ, Bae, JH, Hur, SH, Yoon, KH, Oh, SK, Kim, JH, Kim, SW, Chae, IH, Kim, KS, Hong, YJ & Jeong, MH 2011, 'Long-term safety and efficacy of pitavastatin in patients with acute myocardial infarction (from the Livalo acute myocardial infarction study [LAMIS])', American Journal of Cardiology, vol. 108, no. 11, pp. 1530-1535. https://doi.org/10.1016/j.amjcard.2011.07.009
Suh, Soon Yong ; Rha, Seung-Woon ; Ahn, Tae Hoon ; Shin, Eak Kyun ; Choi, Cheol Ung ; Oh, Dong Joo ; Bae, Jang Ho ; Hur, Seung Ho ; Yoon, Kyung Ho ; Oh, Seok Kyu ; Kim, Jong Hyun ; Kim, Sang Wook ; Chae, In Ho ; Kim, Kee Sik ; Hong, Young Joon ; Jeong, Myung Ho. / Long-term safety and efficacy of pitavastatin in patients with acute myocardial infarction (from the Livalo acute myocardial infarction study [LAMIS]). In: American Journal of Cardiology. 2011 ; Vol. 108, No. 11. pp. 1530-1535.
@article{0b636159016042c49ba263fc7e0daef2,
title = "Long-term safety and efficacy of pitavastatin in patients with acute myocardial infarction (from the Livalo acute myocardial infarction study [LAMIS])",
abstract = "Pitavastatin is a potent lipophilic statin and may play an important role in acute myocardial infarction (AMI) but there have been limited data on the safety and efficacy of pitavastatin in AMI. This study consisted of 1,039 consecutive patients with AMI (74.0{\%} men, mean age 61.4 ± 12.6 years) who presented in 10 major percutaneous coronary intervention centers in Korea from February 2007 through September 2009. Pitavastatin 2 mg/day was routinely administered in patients with AMI from time of presentation. We investigated changes of lipid profiles, biochemical markers, adverse events, and clinical outcomes up to 12 months. During the study 318 events overall occurred in 220 patients (21.2{\%}) who reported <1 treatment emergent adverse event, although 20 events in 14 patients (1.4{\%}) were treatment-related adverse events. Low-density lipoprotein (LDL) cholesterol percent change was -25.6{\%} and LDL cholesterol target attainment was 70.5{\%} at 12-month follow-up. Levels of creatinine phosphokinase, serum glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, and high-sensitivity C-reactive protein decreased significantly during the first 1 month of pitavastatin treatment and were sustained to 12-month follow-up. Major adverse cardiac events occurred in 66 patients (7.3{\%}). All-cause deaths occurred in 32 patients (3.5{\%}) including 19 (2.1{\%}) cardiac deaths and recurrent MIs occurred in 14 (1.6{\%}) and target lesion revascularizations in 42 (4.7{\%}). In conclusion, administration of pitavastatin 2 mg/day in patients with AMI showed 70.5{\%} LDL cholesterol target attainment with good tolerance and was associated with favorable clinical outcomes up to 12 months.",
author = "Suh, {Soon Yong} and Seung-Woon Rha and Ahn, {Tae Hoon} and Shin, {Eak Kyun} and Choi, {Cheol Ung} and Oh, {Dong Joo} and Bae, {Jang Ho} and Hur, {Seung Ho} and Yoon, {Kyung Ho} and Oh, {Seok Kyu} and Kim, {Jong Hyun} and Kim, {Sang Wook} and Chae, {In Ho} and Kim, {Kee Sik} and Hong, {Young Joon} and Jeong, {Myung Ho}",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.amjcard.2011.07.009",
language = "English",
volume = "108",
pages = "1530--1535",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Long-term safety and efficacy of pitavastatin in patients with acute myocardial infarction (from the Livalo acute myocardial infarction study [LAMIS])

AU - Suh, Soon Yong

AU - Rha, Seung-Woon

AU - Ahn, Tae Hoon

AU - Shin, Eak Kyun

AU - Choi, Cheol Ung

AU - Oh, Dong Joo

AU - Bae, Jang Ho

AU - Hur, Seung Ho

AU - Yoon, Kyung Ho

AU - Oh, Seok Kyu

AU - Kim, Jong Hyun

AU - Kim, Sang Wook

AU - Chae, In Ho

AU - Kim, Kee Sik

AU - Hong, Young Joon

AU - Jeong, Myung Ho

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Pitavastatin is a potent lipophilic statin and may play an important role in acute myocardial infarction (AMI) but there have been limited data on the safety and efficacy of pitavastatin in AMI. This study consisted of 1,039 consecutive patients with AMI (74.0% men, mean age 61.4 ± 12.6 years) who presented in 10 major percutaneous coronary intervention centers in Korea from February 2007 through September 2009. Pitavastatin 2 mg/day was routinely administered in patients with AMI from time of presentation. We investigated changes of lipid profiles, biochemical markers, adverse events, and clinical outcomes up to 12 months. During the study 318 events overall occurred in 220 patients (21.2%) who reported <1 treatment emergent adverse event, although 20 events in 14 patients (1.4%) were treatment-related adverse events. Low-density lipoprotein (LDL) cholesterol percent change was -25.6% and LDL cholesterol target attainment was 70.5% at 12-month follow-up. Levels of creatinine phosphokinase, serum glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, and high-sensitivity C-reactive protein decreased significantly during the first 1 month of pitavastatin treatment and were sustained to 12-month follow-up. Major adverse cardiac events occurred in 66 patients (7.3%). All-cause deaths occurred in 32 patients (3.5%) including 19 (2.1%) cardiac deaths and recurrent MIs occurred in 14 (1.6%) and target lesion revascularizations in 42 (4.7%). In conclusion, administration of pitavastatin 2 mg/day in patients with AMI showed 70.5% LDL cholesterol target attainment with good tolerance and was associated with favorable clinical outcomes up to 12 months.

AB - Pitavastatin is a potent lipophilic statin and may play an important role in acute myocardial infarction (AMI) but there have been limited data on the safety and efficacy of pitavastatin in AMI. This study consisted of 1,039 consecutive patients with AMI (74.0% men, mean age 61.4 ± 12.6 years) who presented in 10 major percutaneous coronary intervention centers in Korea from February 2007 through September 2009. Pitavastatin 2 mg/day was routinely administered in patients with AMI from time of presentation. We investigated changes of lipid profiles, biochemical markers, adverse events, and clinical outcomes up to 12 months. During the study 318 events overall occurred in 220 patients (21.2%) who reported <1 treatment emergent adverse event, although 20 events in 14 patients (1.4%) were treatment-related adverse events. Low-density lipoprotein (LDL) cholesterol percent change was -25.6% and LDL cholesterol target attainment was 70.5% at 12-month follow-up. Levels of creatinine phosphokinase, serum glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, and high-sensitivity C-reactive protein decreased significantly during the first 1 month of pitavastatin treatment and were sustained to 12-month follow-up. Major adverse cardiac events occurred in 66 patients (7.3%). All-cause deaths occurred in 32 patients (3.5%) including 19 (2.1%) cardiac deaths and recurrent MIs occurred in 14 (1.6%) and target lesion revascularizations in 42 (4.7%). In conclusion, administration of pitavastatin 2 mg/day in patients with AMI showed 70.5% LDL cholesterol target attainment with good tolerance and was associated with favorable clinical outcomes up to 12 months.

UR - http://www.scopus.com/inward/record.url?scp=80955158527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80955158527&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2011.07.009

DO - 10.1016/j.amjcard.2011.07.009

M3 - Article

VL - 108

SP - 1530

EP - 1535

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 11

ER -